After two years in virtual format, the 90th European Atherosclerosis Society (EAS) Congress made a welcome return as a hybrid meeting, with over 1,300 on-site registrants in Milan, and many more joining online. Among the highlights were discussions of evolving concepts about lipid uptake into arterial walls and latest data from preclinical and clinical studies of novel lipid-lowering therapeutics.
Read the reports:
- New insights on potential atherogenicity of chylomicrons
- Novel ANGPTL3/8 inhibitor lowers TG and cholesterol
- Evinacumab data support remnant cholesterol as a future target
- TRANSLATE-TIMI 70: Vupanorsen significantly lower levels of VLDL-C and remnants
- Silencing of ANGPTL4 via liver-targeted ASOs: Safety data
Reportage by Jenny Bryan